These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 12649145

  • 21. Reduced von Willebrand factor survival in type Vicenza von Willebrand disease.
    Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A.
    Blood; 2002 Jan 01; 99(1):180-4. PubMed ID: 11756169
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Management of inherited von Willebrand disease in 2006.
    Federici AB.
    Semin Thromb Hemost; 2006 Sep 01; 32(6):616-20. PubMed ID: 16977571
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Cellular mechanisms of the hemostatic effects of desmopressin (DDAVP).
    Kaufmann JE, Vischer UM.
    J Thromb Haemost; 2003 Apr 01; 1(4):682-9. PubMed ID: 12871401
    [Abstract] [Full Text] [Related]

  • 29. Effect of exercise, DDAVP, and epinephrine on the factor VIII:C/von Willebrand factor complex in normal dogs and von Willebrand factor deficient Doberman pinscher dogs.
    Meyers KM, Wardrop KJ, Dodds WJ, Brassard J.
    Thromb Res; 1990 Jan 01; 57(1):97-108. PubMed ID: 2105540
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. DDAVP infusion in haemophilia A carriers: different behaviour of plasma factor VIII and von Willebrand factor.
    Casonato A, Dannhauser D, Pontara E, Bertomoro A, Orazi B, Santarossa L, Zerbinati P, Girolami A.
    Blood Coagul Fibrinolysis; 1996 Jul 01; 7(5):549-53. PubMed ID: 8874865
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
    Batlle J, López-Fernández MF, Fraga EL, Trillo AR, Pérez-Rodríguez MA.
    Blood Coagul Fibrinolysis; 2009 Mar 01; 20(2):89-100. PubMed ID: 19786936
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Critical independent regions in the VWF propeptide and mature VWF that enable normal VWF storage.
    Haberichter SL, Jacobi P, Montgomery RR.
    Blood; 2003 Feb 15; 101(4):1384-91. PubMed ID: 12393513
    [Abstract] [Full Text] [Related]

  • 40. Von Willebrand factor (Vonvendi®): the first recombinant product licensed for the treatment of von Willebrand disease.
    Franchini M, Mannucci PM.
    Expert Rev Hematol; 2016 Sep 15; 9(9):825-30. PubMed ID: 27427955
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.